ONECYTE BIOTECHNOLOGIES, INC.

Biotech · Private

Single-cell proteomics platform for rapid high-performing cell-line selection in biologics manufacturing

Grants
$5.1M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: A High Throughput Microfluidics Platform to Measure Secretion from Single Cells$225,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response$256,000
Federal grantDepartment of Health and Human Services · Phase II · A proprietary single-cell analytics platform for accelerating biologics manufacturing$855,264
Federal grantDepartment of Health and Human Services · Phase II · A proprietary single-cell analytics platform for accelerating biologics manufacturing$1,710,528
Federal grantDepartment of Health and Human Services · Phase II · A proprietary single-cell analytics platform for accelerating biologics manufacturing$855,264
Federal grantNational Science Foundation · Phase II · SBIR Phase II:A high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics development$1,186,726
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1693AEON RESPIRE, INC.——
1694NEMUCORE MEDICAL INNOVATIONS, INC.——
1695Epigen Biosciences, Inc.——
1696ONECYTE BIOTECHNOLOGIES, INC.——
1697Igenica——
1698ZabBio, Inc.——
1699EVOQ THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Systems And Methods For High-throughput Cell Line Developmentapplication
  • Systems And Methods For High-throughput Cell Line Developmentapplication
  • Systems And Methods For High-throughput Cell Line Developmentapplication
  • Systems And Methods For High-throughput Cell Line Developmentapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.